Xenetic Biosciences (XBIO) Net Equity Issued and Repurchased (2012 - 2020)

Xenetic Biosciences (XBIO) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $5.4 million in Q4 2020.

• Quarterly Net Equity Issued and Repurchased rose 301.06% year-over-year to $5.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2022 was $5.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $4.0 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased rose to $5.4 million in Q4 2020, from -$2.7 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $5.4 million in Q4 2020 to a low of -$10.7 million in Q3 2019.
• A 3-year average of -$879020.8 and a median of $0.0 in 2018 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2019 — Net Equity Issued and Repurchased sank 623.04% — and 2020, when it soared 301.06%.
• Tracing XBIO's Net Equity Issued and Repurchased over 3 years: stood at -$1.5 million in 2018, then tumbled by 82.37% to -$2.7 million in 2019, then soared by 301.06% to $5.4 million in 2020.
• The last three Net Equity Issued and Repurchased figures came in at $5.4 million (Q4 2020), -$2.7 million (Q4 2019), and -$10.7 million (Q3 2019), per Business Quant data.